Compare Globus Medical Inc. Class A Common Stock (GMED) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs JetBlue Airways Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while JetBlue Airways Corporation trades at $3.03 (market cap $1.26B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 8.1× JetBlue Airways Corporation's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and JetBlue Airways Corporation for 44 Days on average.
| GMED | JBLU | |
|---|---|---|
Market Cap | $10.25B | $1.26B |
Volume | 1,108,124 | 40,642,525 |
Sector | Health | Industrials |
52-Week High | $96.82 | $6.46 |
52-Week Low | $58.33 | $3.01 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $9.76B | $8.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
JetBlue (JBLU) trades at $3.35, down 7.46% today, reflecting persistent bearish sentiment amid negative earnings and high debt. The technical outlook is bearish with key support at $3, while fundamentals show revenue near $9.1B but net losses widening, with a negative ROE of -44.36%. Recent news includes route expansion in Colombia but also capacity cuts and elevated fuel costs pressuring margins.
The stock faces significant headwinds from consecutive quarterly losses and rising leverage, yet analyst consensus suggests a $5.89 price target implies potential upside if cost controls improve. Key risks include volatile fuel prices, competitive pressures, and execution of the JetForward strategy amidst a challenging macroeconomic backdrop for airlines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
